Description
CCG 232601 is a selective and orally bioactive inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 µM (SRE.L assay)) as a potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibits the development of bleomycin-induced dermal fibrosis in mice when administered orally